Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
|
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG. |
Generalized Myasthenia Gravis | Phase3 |
China Denmark Greece Israel Italy Japan Poland Portugal Spain United Kingdom United States View all
|
NCT06517758 |
|
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa |
Hidradenitis Suppurativa | Phase3 |
Argentina Austria Belgium Canada Colombia Czechia France Germany Greece Hungary Malaysia Mexico Poland Puerto Rico Romania Spain Turkey (Türkiye) United Kingdom United States View all
|
NCT06840392 |
|
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. |
Chronic Myeloid Leukemia (CML) | Phase2 | France | NCT06514534 |
|
A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A. |
Charcot-Marie-Tooth Disease, Type 1A | Phase1 | Canada | NCT07140614 |
|
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD |
Atherosclerotic Cardiovascular Disease (ASCVD) | Phase3 |
China Hong Kong Puerto Rico Taiwan United Kingdom United States View all
|
NCT06813911 |
|
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. |
Oligometastatic Prostate Cancer (OMPC) | Phase3 |
Argentina Australia Belgium Brazil Canada China Czechia France Germany Greece Hungary Israel Italy Japan Malaysia Mexico Netherlands Puerto Rico Singapore Slovakia Spain Switzerland Taiwan United Kingdom United States View all
|
NCT05939414 |
|
A Post Marketing Surveillance on Piqray in Korea |
Breast Cancer | South Korea | NCT05293470 | |
|
Secukinumab Open Label Roll-over Extension Protocol |
Autoimmunity, Inflammation | Phase4 |
China Colombia Czechia Guatemala Poland Russia Spain United States View all
|
NCT04638647 |
|
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors |
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma | Phase1 |
Canada South Korea United States |
NCT07006727 |
|
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence |
Breast Neoplasms |
Austria Germany |
NCT06830720 |